文献速递甲状腺疾病性腺与生殖内分泌

治疗反应状态可极好地预测既往分化型甲状腺癌患者妊娠相关结构性疾病的进展

Response to Therapy Status Is an Excellent Predictor of Pregnancy-Associated Structural Disease Progression in Patients Previously Treated for Differentiated Thyroid Cancer.
PubMed 文献 · Thyroid · 2017-01-19

该回顾性研究纳入235例在Memorial Sloan Kettering Cancer Center接受分化型甲状腺癌初始治疗后足月妊娠的女性,按2015年美国甲状腺协会指南以孕前治疗反应状态分层。孕前为极好、不确定或生化不完全反应者产后均无结构性可识别疾病;孕前结构性不完全反应者中29%(11/38)出现结构性进展,仅8%(3/38)需追加治疗。

要点

  • 孕前极好、不确定或生化不完全反应者产后均无结构性可识别疾病。
  • 孕前结构性不完全反应者中29%(11/38)产后出现结构性进展。
  • 孕前结构性不完全反应者仅8%(3/38)需追加治疗,92%继续观察。

核心结论

  • 孕前治疗反应状态是既往分化型甲状腺癌女性妊娠相关疾病进展的极好预测因素。
  • 孕前极好、不确定或生化不完全反应者足月分娩后均未出现结构性可识别疾病。
  • 孕前已知结构性病变者近三分之一出现结构性进展,但仅少数需追加治疗。

研究设计与样本

  • 回顾性研究,纳入1997年至2015年在Memorial Sloan Kettering Cancer Center随访、分化型甲状腺癌初始治疗后足月妊娠的235例女性。
  • 按2015年美国甲状腺协会甲状腺癌指南以孕前治疗反应状态进行评估。

主要发现

  • 妊娠后结构性疾病复发/进展见于5%(11/235)的患者。
  • 产后3-12个月评估时,孕前极好、不确定或生化不完全反应者均持续无结构性可识别疾病证据。
  • 孕前结构性不完全反应者中,产后结构性进展(定义为已知病灶尺寸增加≥3 mm或发现新转移灶)见于29%(11/38)。
  • 孕前结构性不完全反应者中,产后最初数年仅8%(3/38)被建议追加治疗,其余92%继续观察。

关键数值与推荐

  • 结构性进展定义为已知病灶尺寸增加≥3 mm或发现新转移灶。
  • 治疗反应状态按2015年美国甲状腺协会甲状腺癌指南于孕前评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnancy may be associated with an increased risk of recurrence/progression of differentiated thyroid cancer (DTC). However, it is unclear if the impact of pregnancy would differ based on pre-pregnancy response to therapy status. The objective of this study was to investigate the risk of recurrence/progression of DTC, applying the response to therapy assessments to pre-pregnancy status as recommended by the 2015 American Thyroid Association thyroid cancer guidelines. METHODS: This was a retrospective review of 235 women followed at Memorial Sloan Kettering Cancer Center for DTC who had a term pregnancy after initial treatment for DTC between 1997 and 2015. RESULTS: Structural disease recurrence/progression after pregnancy was documented in 5% (11/235) of the patients. When evaluated 3-12 months after delivery, patients who had an excellent, indeterminate, or biochemical incomplete response before pregnancy continued to show no evidence of structurally identifiable disease. Conversely, in women with a structural incomplete response to therapy prior to pregnancy, structural progression (defined as ≥3 mm increase in the size of known disease or identification of new metastatic foci) was identified after delivery in 29% (11/38). However, additional therapy was recommended during the first postpartum years in only 8% (3/38) of those patients who had a structural incomplete response to therapy prior to pregnancy, while the remainder (92%) continued to be followed with observation. CONCLUSION: None of the patients with an excellent, indeterminate, or biochemical incomplete response to therapy prior to pregnancy developed structurally identifiable disease after a full-term delivery. Even though structural disease progression was seen in almost a third of the patients with known structural disease prior to pregnancy, only a minority of these patients had changes sufficient to warrant additional therapy. These data confirm that pre-pregnancy response to therapy status is an excellent predictor of pregnancy-associated disease progression in women previously treated for DTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Rakhlin L, Fish S, Tuttle RM, et al. Response to Therapy Status Is an Excellent Predictor of Pregnancy-Associated Structural Disease Progression in Patients Previously Treated for Differentiated Thyroid Cancer. Thyroid. 2017. PMID: 27835925. doi:10.1089/thy.2016.0501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。